Drug Science just launched the largest study on medical cannabis in Europe

Drug Science has launched the project TWENTY21. The aim is to collect data from 20,000 patients and provide sufficient proof of efficacy for the National Health Service to pay for medical cannabis treatment. The project TWENTY21 is aimed at patients with the conditions where alternative treatment has failed. The aim is to create the largest proof of the efficacy of medical cannabis in Europe.

The first patient registry for medical cannabis in Europe has recently been launched in the United Kingdom. It will be the largest study on medical cannabis in Europe.

The register will collect data from 20,000 patients covering seven different areas of application. The scientists hope that it will provide sufficient proof of efficacy for the NHS to start paying for treatment with medical cannabis.

Cannabis is one of the world’s most talked-about topics. Medical cannabis is a sector that brings profit to the cannabis industry.

One potentially useful hemp news tool is Hemp.im, which focuses on the latest marijuana news, social change, economic trends, and medical information.

You can find more information about the cannabis industry and other important news in the cannabis sector in the Hemp.im app.

Medical cannabis in Europe is too expensive

The U.K.’s leading independent Drug Science has launched a major study on medical cannabis to improve the evidence base on medical cannabis with extensive data from practical use.

A total of 20,000 patients with various diseases are to be included in the TWENTY21 project. The aim is to create the largest proof of the efficacy of medical cannabis in Europe.

Drug Science expects that the results will provide sufficient evidence to help doctors gain more confidence in the treatment.

It also aims to convince decision-makers such as the National Health Service (NHS) of the benefits a wider acceptance of medical cannabis would have on human health.

The aim is for the NHS to cover the cost of treatment, which has not been the case to date.

“Medical cannabis is still unreachable for far too many,” said drug specialist and activist David Nutt, who leads the project.

“Patients are left untreated, have substantial debts due to the cost of private prescriptions, or are criminalized because they are forced to turn to the black market.”

“They don’t deserve any of this. The situation regarding prescription must change urgently,” demanded the psychiatrist and psychopharmacologist.

Which areas of medical cannabis in Europe are being studied?

TWENTY21 is aimed for patients with the following conditions where alternative treatment has failed: chronic pain, anxiety disorder, epilepsy, multiple sclerosis, post-traumatic stress disorder (PTSD), Tourette’s syndrome.

It is emphasized that TWENTY21 is not a randomized controlled trial in which some patients would receive a placebo.

Rather, real-life data will be collected to document efficacy, safety, quality of life (QALY) and patient-reported results for the types of medical cannabis used in these diseases.

All participants will receive the preparations at affordable costs, subsidized by partner companies from the pharmaceutical industry and by Drug Science itself.

__

(Featured image by Alvaro Reyes via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Deutsche Apotheker Zeitung Online, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.